Longeveron (NASDAQ:LGVN) Stock Breaks Above 50 Day Moving Average – What’s Next?

Longeveron Inc. (NASDAQ:LGVN – Get Free Report)’s stock price crossed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $3.08 and traded as high as $3.30. Longeveron shares last traded at $3.30, with a volume of 131,307 shares traded.

Wall Street Analyst Weigh In

LGVN has been the subject of a number of research reports. Weiss Ratings cut Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. Wall Street Zen raised Longeveron from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $80.00.

Check Out Our Latest Research Report on Longeveron

Longeveron Stock Performance

The company’s 50-day simple moving average is $3.08 and its 200 day simple moving average is $6.47. The company has a market cap of $10.53 million, a PE ratio of -0.33 and a beta of -0.09.

Longeveron (NASDAQ:LGVN – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.75) by $1.56. The business had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.33 million. Longeveron had a negative return on equity of 223.19% and a negative net margin of 1,977.59%. Analysts forecast that Longeveron Inc. will post -7.20 EPS for the current year.

Institutional Investors Weigh In On Longeveron

A hedge fund recently bought a new stake in Longeveron stock. ADAR1 Capital Management LLC purchased a new stake in Longeveron Inc. (NASDAQ:LGVN – Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 200,000 shares of the company’s stock, valued at approximately $208,000. ADAR1 Capital Management LLC owned approximately 0.86% of Longeveron at the end of the most recent reporting period. Institutional investors and hedge funds own 10.01% of the company’s stock.

Longeveron Company Profile

(Get Free Report)

Longeveron Inc. is a clinical-stage biotechnology company focused on developing regenerative medicines for serious and life-threatening conditions. The company’s research centers on cell-based therapies intended to support tissue repair, reduce harmful inflammation and promote the body’s natural healing processes. Longeveron’s lead investigational product is Lomecel-B, an allogeneic cell therapy derived from bone marrow obtained from healthy adult donors. The company has evaluated Lomecel-B in clinical programs addressing hypoplastic left heart syndrome, a rare congenital heart defect in infants, as well as Alzheimer’s disease and aging-related frailty.

Recommended Stories

Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.